Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2009_669 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will compare three consistency lots of ProQuad to each other as well as to M-M-R II and Varivax, administered concomitantly at different injection sites, with respect to immunogenicity, safety, and tolerability.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | ProQuad Lot 1 |
|
| 2 | Experimental | ProQuad Lot 2 |
|
| 3 | Experimental | ProQuad Lot 3 |
|
| 4 | Active Comparator | M-M-R II + Varivax |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live | Biological | A Single 0.5 mL subcutaneous injection at Day 0 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Postvaccination Varicella Antibody Titer ≥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL | Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially With Varicella Antibody Titer < 1.25 gpELISA units/mL at Baseline | 6 weeks Postvaccination |
| Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥ 120 mIU/mL | Antibody Response to Measles at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer < 120 mIU/mL) to Measles at Baseline | 6 weeks Postvaccination |
| Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥ 10 Ab Units/mL | Antibody Response to Mumps at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer < 10 Ab units/mL) to Mumps at Baseline | 6 weeks Postvaccination |
| Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥ 10 IU/mL | Antibody Response to Rubella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer < 10 IU/mL) to Rubella at Baseline | 6 weeks Postvaccination |
| Antibody Response to Varicella for Subjects Initially With Varicella Antibody Titer < 1.25 gpELISA Units/mL at Baseline - Geometric Mean Titer | Postvaccination observed Geometric Mean Titer of antibody to Varicella | 6 weeks Postvaccination |
| Antibody Response to Measles for Subjects Initially Seronegative (a Titer < 120 mIU/mL) to Measles at Baseline - Geometric Mean Titer |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 16804432 | Result | Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schodel F, Kuter BJ; Consistency Lot Study Group for ProQuad. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J. 2006 Jul;25(7):615-22. doi: 10.1097/01.inf.0000220209.35074.0b. |
Not provided
Not provided
Not provided
35 clinical sites in the United States and 5 clinical sites in Canada
Date of first participant visit: 12-Apr-2000
Date of last participant visit: 11-May-2001
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | ProQuad™ Lot 1 | ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL. |
| FG001 | ProQuad™ Lot 2 |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Comparator: Varivax | Biological | A Single 0.5 mL subcutaneous injection at Day 0 |
|
| Comparator: M-M-R II | Biological | A Single 0.5 mL subcutaneous injection at Day 0 |
|
Postvaccination observed Geometric Mean Titer of antibody to Measles.
| 6 weeks Postvaccination |
| Antibody Response to Mumps for Subjects Initially Seronegative (a Titer < 10 Ab Units/mL) to Mumps at Baseline - Geometric Mean Titer | Postvaccination observed Geometric Mean Titer of antibody to Mumps. | 6 weeks Postvaccination |
| Antibody Response to Rubella for Subjects Initially Seronegative (a Titer < 10 IU/mL) to Rubella at Baseline - Geometric Mean Titer | Postvaccination observed Geometric Mean Titer of antibody to Rubella | 6 weeks Postvaccination |
| Number of Participants With Serious Vaccine-related CAEs | Subjects with a serious vaccine-related CAE (an AE which is assessed by an investigator/qualified physician as being related to study vaccine and results in death, persistent or significant disability/incapacity, prolongs an existing inpatient hospitalization, is life-threatening, a congenital anomaly/birth defect, a cancer, or an overdose). | 6 weeks Postvaccination |
ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL.
| FG002 | ProQuad™ Lot 3 | ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL. |
| FG003 | M-M-R™ II + VARIVAX™ | VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0. |
| Vaccinated at Visit 1 |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | ProQuad™ Lot 1 | ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL. |
| BG001 | ProQuad™ Lot 2 | ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL. |
| BG002 | ProQuad™ Lot 3 | ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL. |
| BG003 | M-M-R™ II + VARIVAX™ | VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0. |
| BG004 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Months |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Postvaccination Varicella Antibody Titer ≥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL | Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially With Varicella Antibody Titer < 1.25 gpELISA units/mL at Baseline | Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, Varicella Antibody Titer <1.25 gpELISA units/mL at baseline, and followed protocol procedures. | Posted | Number | Participants | 6 weeks Postvaccination |
|
|
| |||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥ 120 mIU/mL | Antibody Response to Measles at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer < 120 mIU/mL) to Measles at Baseline | Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures. | Posted | Number | Participants | 6 weeks Postvaccination |
| |||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥ 10 Ab Units/mL | Antibody Response to Mumps at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer < 10 Ab units/mL) to Mumps at Baseline | Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures. | Posted | Number | Participants | 6 weeks Postvaccination |
| |||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥ 10 IU/mL | Antibody Response to Rubella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer < 10 IU/mL) to Rubella at Baseline | Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures. | Posted | Number | Participants | 6 weeks Postvaccination |
| |||||||||||||||||||||||||||||||||||||
| Primary | Antibody Response to Varicella for Subjects Initially With Varicella Antibody Titer < 1.25 gpELISA Units/mL at Baseline - Geometric Mean Titer | Postvaccination observed Geometric Mean Titer of antibody to Varicella | Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, Varicella Antibody Titer < 1.25 gpELISA units/mL at baseline, and followed protocol procedures. | Posted | Mean | 95% Confidence Interval | gpELISA | 6 weeks Postvaccination |
| ||||||||||||||||||||||||||||||||||||
| Primary | Antibody Response to Measles for Subjects Initially Seronegative (a Titer < 120 mIU/mL) to Measles at Baseline - Geometric Mean Titer | Postvaccination observed Geometric Mean Titer of antibody to Measles. | Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures. | Posted | Mean | 95% Confidence Interval | mIU/mL | 6 weeks Postvaccination |
| ||||||||||||||||||||||||||||||||||||
| Primary | Antibody Response to Mumps for Subjects Initially Seronegative (a Titer < 10 Ab Units/mL) to Mumps at Baseline - Geometric Mean Titer | Postvaccination observed Geometric Mean Titer of antibody to Mumps. | Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures. | Posted | Mean | 95% Confidence Interval | ELISA AB units | 6 weeks Postvaccination |
| ||||||||||||||||||||||||||||||||||||
| Primary | Antibody Response to Rubella for Subjects Initially Seronegative (a Titer < 10 IU/mL) to Rubella at Baseline - Geometric Mean Titer | Postvaccination observed Geometric Mean Titer of antibody to Rubella | Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures. | Posted | Mean | 95% Confidence Interval | ELISA AB units | 6 weeks Postvaccination |
| ||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With Serious Vaccine-related CAEs | Subjects with a serious vaccine-related CAE (an AE which is assessed by an investigator/qualified physician as being related to study vaccine and results in death, persistent or significant disability/incapacity, prolongs an existing inpatient hospitalization, is life-threatening, a congenital anomaly/birth defect, a cancer, or an overdose). | All subjects with follow-up for safety were included in the analysis. | Posted | Number | Participants | 6 weeks Postvaccination |
|
Not provided
Number of participants reported as "At Risk" is the number of participants with follow-up.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | ProQuad™ Lot 1 | ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL. | 6 | 969 | 793 | 969 | ||
| EG001 | ProQuad™ Lot 2 | ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL. | 8 | 950 | 758 | 950 | ||
| EG002 | ProQuad™ Lot 3 | ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL. | 11 | 941 | 769 | 941 | ||
| EG003 | M-M-R™ II + VARIVAX™ | VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0. | 11 | 993 | 785 | 993 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Seizure, febrile | Nervous system disorders | Merck CRISP | Non-systematic Assessment |
| |
| Seizure disorder | Nervous system disorders | Merck CRISP | Non-systematic Assessment |
| |
| Accidental ingestion | Injury, poisoning and procedural complications | Merck CRISP | Non-systematic Assessment |
| |
| Fever | General disorders | Merck CRISP | Systematic Assessment |
| |
| Infection, urinary tract | Infections and infestations | Merck CRISP | Non-systematic Assessment |
| |
| Pneumonia | Infections and infestations | Merck CRISP | Non-systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | Merck CRISP | Non-systematic Assessment |
| |
| Bronchiolitis | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Wheezing | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Vomitting | Gastrointestinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Otitis media | Ear and labyrinth disorders | Merck CRISP | Non-systematic Assessment |
| |
| Fracture, humerus, right | Injury, poisoning and procedural complications | Merck CRISP | Non-systematic Assessment |
| |
| Fracture, radius, right | Injury, poisoning and procedural complications | Merck CRISP | Non-systematic Assessment |
| |
| Respiratory distress | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Hypoxemia | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Infection, RSV | Infections and infestations | Merck CRISP | Non-systematic Assessment | Infection, respiratory syncytial virus (RSV) |
|
| Asthma | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Gastroenteritis, Infectious | Infections and infestations | Merck CRISP | Non-systematic Assessment |
| |
| Gastroenteritis | Gastrointestinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Infection, viral | Infections and infestations | Merck CRISP | Non-systematic Assessment |
| |
| Hypovolemia | Metabolism and nutrition disorders | Merck CRISP | Non-systematic Assessment |
| |
| Trauma | Injury, poisoning and procedural complications | Merck CRISP | Non-systematic Assessment |
| |
| Bite, animal | Injury, poisoning and procedural complications | Merck CRISP | Non-systematic Assessment |
| |
| Cellulitis | Skin and subcutaneous tissue disorders | Merck CRISP | Non-systematic Assessment |
| |
| Pyelonephritis | General disorders | Merck CRISP | Non-systematic Assessment |
| |
| Drug abuse | Injury, poisoning and procedural complications | Merck CRISP | Non-systematic Assessment | Drug abuse refers to cocaine metabolites found in subject's urine. |
|
| Allergy | Immune system disorders | Merck CRISP | Non-systematic Assessment |
| |
| Diarrhea | Gastrointestinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Colitis | Gastrointestinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Breathing Pattern Abnormal | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Fever | General disorders | Merck CRISP | Systematic Assessment |
| |
| Infection, Viral | Infections and infestations | Merck CRISP | Non-systematic Assessment |
| |
| Trauma | Injury, poisoning and procedural complications | Merck CRISP | Non-systematic Assessment |
| |
| Anorexia | Metabolism and nutrition disorders | Merck CRISP | Non-systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Diarrhea | Gastrointestinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Gastroenteritis | Gastrointestinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Gastroenteritis, Infectious | Infections and infestations | Merck CRISP | Non-systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Irritability | Psychiatric disorders | Merck CRISP | Non-systematic Assessment |
| |
| Asthma | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Bronchiolitis | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Congestion, Nasal | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Congestion, Respiratory | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Infection, Respiratory, Upper | Infections and infestations | Merck CRISP | Non-systematic Assessment |
| |
| Influenza | Infections and infestations | Merck CRISP | Non-systematic Assessment |
| |
| Laryngotracheobronchitis | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Pharyngitis | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Rhinorrhea | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Sinusitis | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Wheezing | Respiratory, thoracic and mediastinal disorders | Merck CRISP | Non-systematic Assessment |
| |
| Bite/Sting, Non-Venomous | Injury, poisoning and procedural complications | Merck CRISP | Non-systematic Assessment |
| |
| Dermatitis, Contact | Skin and subcutaneous tissue disorders | Merck CRISP | Non-systematic Assessment |
| |
| Eczema | Skin and subcutaneous tissue disorders | Merck CRISP | Non-systematic Assessment |
| |
| Laceration | Skin and subcutaneous tissue disorders | Merck CRISP | Non-systematic Assessment |
| |
| Miliaria Rubra | Skin and subcutaneous tissue disorders | Merck CRISP | Non-systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | Merck CRISP | Non-systematic Assessment |
| |
| Rash, Diaper | Skin and subcutaneous tissue disorders | Merck CRISP | Non-systematic Assessment |
| |
| Rash, Measles/Rubella-Like | Skin and subcutaneous tissue disorders | Merck CRISP | Systematic Assessment |
| |
| Rash, Varicella-Like | Skin and subcutaneous tissue disorders | Merck CRISP | Systematic Assessment |
| |
| Urticaria | Skin and subcutaneous tissue disorders | Merck CRISP | Non-systematic Assessment |
| |
| Viral Exanthema | Infections and infestations | Merck CRISP | Non-systematic Assessment |
| |
| Conjunctivitis | Eye disorders | Merck CRISP | Non-systematic Assessment |
| |
| Otitis | Ear and labyrinth disorders | Merck CRISP | Non-systematic Assessment |
| |
| Otitis Media | Ear and labyrinth disorders | Merck CRISP | Non-systematic Assessment |
| |
| Ecchymosis (ProQuad Injection-site) | Skin and subcutaneous tissue disorders | Merck CRISP | Non-systematic Assessment |
| |
| Erythema (ProQuad Injection-site) | Skin and subcutaneous tissue disorders | Merck CRISP | Systematic Assessment |
| |
| Pain/Tenderness/Soreness (ProQuad Injection-site) | Skin and subcutaneous tissue disorders | Merck CRISP | Systematic Assessment |
| |
| Rash (ProQuad Injection-site) | Skin and subcutaneous tissue disorders | Merck CRISP | Non-systematic Assessment |
| |
| Swelling (ProQuad Injection-site) | Skin and subcutaneous tissue disorders | Merck CRISP | Systematic Assessment |
| |
| Ecchymosis (Varivax Injection-site) | Skin and subcutaneous tissue disorders | Merck CRISP | Non-systematic Assessment |
| |
| Erythema (Varivax Injection-site) | Skin and subcutaneous tissue disorders | Merck CRISP | Systematic Assessment |
| |
| Pain/Tenderness/Soreness (Varivax Injection-site) | Skin and subcutaneous tissue disorders | Merck CRISP | Systematic Assessment |
| |
| Rash (Varivax Injection-site) | Skin and subcutaneous tissue disorders | Merck CRISP | Non-systematic Assessment |
| |
| Swelling (Varivax Injection-site) | Skin and subcutaneous tissue disorders | Merck CRISP | Systematic Assessment |
| |
| Ecchymosis (M-M-R II Injection-site) | Skin and subcutaneous tissue disorders | Merck CRISP | Non-systematic Assessment |
| |
| Erythema (M-M-R II Injection-site) | Skin and subcutaneous tissue disorders | Merck CRISP | Systematic Assessment |
| |
| Pain/Tenderness/Soreness (M-M-R II Injection-site) | Skin and subcutaneous tissue disorders | Merck CRISP | Systematic Assessment |
| |
| Swelling (M-M-R II Injection-site) | Skin and subcutaneous tissue disorders | Merck CRISP | Systematic Assessment |
|
One additional subject received M-M-R™ II and ProQuad™ vaccines at the same visit in error; this child was excluded from all immunogenicity and safety summaries.
Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Senior Vice President, Global Clinical Development | Merck Sharp & Dohme Corp | 1-800-672-6372 |
| ID | Term |
|---|---|
| D008457 | Measles |
| D009107 | Mumps |
| D012409 | Rubella |
| D002644 | Chickenpox |
| ID | Term |
|---|---|
| D018185 | Morbillivirus Infections |
| D018184 | Paramyxoviridae Infections |
| D018701 | Mononegavirales Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
| D019351 | Rubulavirus Infections |
| D010309 | Parotitis |
| D010305 | Parotid Diseases |
| D012466 | Salivary Gland Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D018355 | Rubivirus Infections |
| D014036 | Togaviridae Infections |
| D000073618 | Varicella Zoster Virus Infection |
| D006566 | Herpesviridae Infections |
| D004266 | DNA Virus Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C050102 | measles, mumps, rubella, varicella vaccine |
Not provided
Not provided
Not provided
| Male |
|
| Asian/Pacific |
|
| Caucasian |
|
| Hispanic |
|
| Native American |
|
| Other |
|
| OG003 |
| M-M-R™ II + VARIVAX™ |
VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0. |
|
|
| M-M-R™ II + VARIVAX™ |
VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0. |
|
|
| M-M-R™ II + VARIVAX™ |
VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0. |
|
|
| M-M-R™ II + VARIVAX™ |
VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0. |
|
|
| M-M-R™ II + VARIVAX™ |
VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0. |
|
|
| M-M-R™ II + VARIVAX™ |
VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0. |
|
|
| M-M-R™ II + VARIVAX™ |
VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0. |
|
|
| OG003 |
| M-M-R™ II + VARIVAX™ |
VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0. |
|
|